信迪利单抗联合紫杉醇、奥沙利铂及替吉奥用于局部进展期胃癌新辅助治疗的疗效  

Efficacy evaluation of sindillimab combined with paclitaxel,oxaliplatin and tegafur chemotherapy for neoadjuvant therapy of locally advanced gastric cancer

作　　者：韩国达[1] 林叶成 张雷[2] 张晓玲[3] 魏晓楠[1] 刘旭 谢艳超 HAN Guoda;LIN Yecheng;ZHANG Lei;ZHANG Xiaoling;WEI Xiaonan;LIU Xu;XIE Yanchao(Department of Gastrointestinal Surgery,Cangzhou Central Hospital,Hebei Cangzhou 061001,China;Department of Laboratory,Cangzhou Central Hospital,Hebei Cangzhou 061001,China;Department of Pathology,Cangzhou Central Hospital,Hebei Cangzhou 061001,China)

机构地区：[1]沧州市中心医院胃肠外一科,河北沧州061001 [2]沧州市中心医院检验科,河北沧州061001 [3]沧州市中心医院病理科,河北沧州061001

出　　处：《临床药物治疗杂志》2025年第3期48-53,共6页Clinical Medication Journal

基　　金：吴阶平医学基金会临床科研专项资助基金支持项目(320.6750.2021-2-99)。

摘　　要：目的探讨信迪利单抗联合白蛋白结合型紫杉醇、奥沙利铂及替吉奥化疗方案应用于局部进展期胃癌新辅助治疗的疗效。方法选取沧州市中心医院2021年8月至2022年12月局部进展期胃或胃食管结合部腺癌患者,术前给予4个周期信迪利单抗联合白蛋白紫杉醇、奥沙利铂及替吉奥化疗方案治疗后行手术治疗。观察患者手术的肿瘤完全切除率(R0切除率)、手术并发症情况以及术后病理的完全缓解率(pCR),评估新辅助治疗的疗效,并随访1年无病生存期(DFS)和总生存(OS)率。结果共纳入30例局部进展期胃癌患者,其中16例(53.3%)患者达到客观缓解(ORR),28例(93.3%)患者达到疾病控制(DCR),17例(56.7%)患者达到降期,肿瘤退缩分级(TRG)方面:TRG 0、TRG 1、TRG 2和TRG 3的肿瘤退缩分级分别为16.7%、13.3%、43.3%和16.7%;pCR率为16.7%,R0切除率为90.0%,且术后并发症可控,1年DFS率为92.6%,1年OS率为96.7%。结论信迪利单抗联合白蛋白结合型紫杉醇、奥沙利铂、替吉奥化疗用于局部进展期胃癌新辅助治疗的疗效较好,短期生存可获益。Objective To investigate the efficacy of sintilimab combined with albumin-bound paclitaxel,oxaliplatin,and tegafur chemotherapy for neoadjuvant therapy of locally advanced gastric cancer.Methods Patients with locally advanced gastric or gastroesophageal junction adenocarcinoma treated at Cangzhou Central Hospital from August 2021 to December 2022 were selected.They received 4 cycles of sintilimab combined with albumin-bound paclitaxel,oxaliplatin,and tegafur chemotherapy before surgery.The tumor complete resection rate(R0 resection rate),surgical complications,and pathological complete response rate(pCR)were observed to evaluate the efficacy of neoadjuvant therapy.Patients were followed up for 1 year to assess disease-free survival(DFS)and overall survival(OS)rates.Results A total of 30 patients with locally advanced gastric cancer were included.Among them,16 patients(53.3%)achieved an objective response rate(ORR),28 patients(93.3%)achieved disease control rate(DCR),and 17 patients(56.7%)achieved downstaging.Tumor regression grading(TRG)results were as follows:TRG 0,TRG 1,TRG 2,and TRG 3 accounted for 16.7%,13.3%,43.3%,and 16.7%,respectively.The pCR rate was 16.7%,and the R0 resection rate was 90.0%.Postoperative complications were manageable.The 1-year DFS rate was 92.6%,and the 1-year OS rate was 96.7%.Conclusion Sintilimab combined with albumin-bound paclitaxel,oxaliplatin,and tegafur chemotherapy demonstrates favorable efficacy in neoadjuvant therapy for locally advanced gastric cancer,with short-term survival benefits.

关 键 词：胃癌 新辅助化疗 信迪利单抗 疗效 

分 类 号：R979.1[医药卫生—药品] R735.2[医药卫生—药学]